View addendum to Health Center COVID-19 Survey Tool Questions and related user guide for participating health centers in the Health Center COVID-19 Vaccine Program.
National Summary Report
Latest data from January 14, 2022
HRSA uses the information collected to: optimize COVID-19 testing and vaccination; track health center capacity and the impact of COVID-19 on operations, patients, and staff; and better understand training and technical assistance, funding, and other health center resource needs.
Health Center COVID-19 Survey Tool Questions
Health Center COVID-19 Survey Tool User Guide
Health Center Program Look-Alike Survey Data for COVID-19
COVID-19 Health Center Survey Interactive Data Dashboards
View cumulative vaccination data nationally; by state, territory, and freely associated state; and among patients identified as racial and/or ethnic minorities. New data views: total vaccinations (all sources) and Health Center Vaccine Program (federal allocations only).
View operational data, including testing capacity, vaccinations initiated and completed, temporary closures, staff ability to work, and visits conducted virtually.
View COVID-19 testing data by race/ethnicity.
Note: The dashboard data are updated weekly using Health Center COVID-19 Survey data.
Number of Health Center respondents = 1089 (79% of all Health Centers)
Data represent information provided by health centers from a single, specified reporting date. Summary information across report dates is not comparable due to differences in which health centers responded for a given report date.
Patients Tested
| Metrics | Value |
|---|---|
| Patients Tested for COVID-19, Virus Detection (PCR, antigen)1 | 864,274 |
| Racial and/or Ethnic Minority Patients Tested for COVID-19, Virus Detection (PCR, antigen) | 64.24% |
| Patients Tested Positive for COVID-19, Virus Detection (PCR, antigen)1 | 291,458 |
| Racial and/or Ethnic Minority Patients | 66.53% |
Patients Tested by Race and Ethnicity
| Race/Ethnicity | Patients Tested by race and ethnicity, Virus Detection (PCR, antigen)2 | Patients Tested Positive by race and ethnicity, Virus Detection (PCR, antigen)2 |
|---|---|---|
| White, Non-Hispanic/Latino Patients | 30.70% | 28.92% |
| White, Hispanic/Latino Patients | 21.78% | 24.53% |
| Black/African American, Non-Hispanic/Latino Patients | 16.02% | 15.75% |
| Black/African American, Hispanic/Latino Patients | 1.10% | 1.28% |
| Asian Patients3 | 3.02% | 2.70% |
| American Indian/Alaska Native Patients3 | 1.13% | 1.05% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.95% | 0.89% |
| Patients with More Than One Race3 | 3.24% | 3.08% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 7.92% | 8.21% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.57% | 2.25% |
| Unreported/Refused to Report Race and Ethnicity | 11.57% | 11.34% |
Patients Vaccinated
| Metrics | Value |
|---|---|
| COVID-19 Immunization Series Initiated | 139,313 |
| Racial and/or Ethnic Minority Patients Who Initiated COVID-19 Immunization | 82.95% |
| COVID-19 Immunization Series Completed | 110,193 |
| Racial and/or Ethnic Minority Patients Who Completed COVID-19 Immunization | 82.22% |
| COVID-19 Immunization Series Additional | 305,563 |
| Racial and/or Ethnic Minority Patients Who Received an Additional Dose of COVID-19 Vaccine | 76.96% |
Vaccinations by Race and Ethnicity
| Race/Ethnicity | Patient COVID-19 Immunization Series Initiated2 | Patient COVID-19 Immunization Series Completed2 | Patient COVID-19 Immunization Series Additional2 |
|---|---|---|---|
| White, Non-Hispanic/Latino Patients | 14.56% | 15.15% | 20.27% |
| White, Hispanic/Latino Patients | 29.91% | 28.12% | 23.41% |
| Black/African American, Non-Hispanic/Latino Patients | 12.60% | 12.43% | 9.16% |
| Black/African American, Hispanic/Latino Patients | 1.19% | 1.17% | 0.96% |
| Asian Patients3 | 4.52% | 7.21% | 12.94% |
| American Indian/Alaska Native Patients3 | 1.02% | 0.92% | 1.80% |
| Native Hawaiian/Other Pacific Islander Patients3 | 1.10% | 1.24% | 1.48% |
| Patients with More Than One Race3 | 3.81% | 4.59% | 4.77% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 16.67% | 14.40% | 13.17% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 2.43% | 2.50% | 2.51% |
| Unreported/Refused to Report Race and Ethnicity | 12.19% | 12.29% | 9.52% |
Testing Logistics
Average Turnaround Time for COVID-19 Test Results, Virus Detection (PCR, antigen)
| Metrics | Value |
|---|---|
| Less Than 1 Hour | 18.09% |
| 1 to 24 Hours | 22.41% |
| More Than 24 Hours | 57.76% |
| N/A | 1.74% |
Vaccine Logistics
Challenges in Deploying the COVID Vaccine
| Metrics | Value |
|---|---|
| Financial reimbursement for costs associated with vaccine administration | 4.87% |
| Staffing to administer the vaccine | 45.45% |
| Vaccine confidence | 29.29% |
| Vaccine storage capacity | 2.39% |
| Vaccine supply | 4.50% |
| Other | 5.42% |
| None | 30.85% |
Operations and Staff
| Metrics | Value |
|---|---|
| COVID-19 Vaccine Doses Received Only From Health Center COVID-19 Vaccine Program | 21.12% |
| Average Percent of Health Center Visits Conducted Virtually | 21.92% |
Mobile Vans, Pop-Up Clinics, and School-Based Sites
| Metrics | Value |
|---|---|
| Percent of Health Centers Hosting Mobile Vans, Pop-Up, and/or School-Based Clinics | 34.99% |
| Number of Mobile Van Sites | 356 |
| Number of Pop-up Clinics | 1,023 |
| Number of School-Based Vaccination Sites | 413 |
| Number of Family Vaccination Clinics | 1,075 |
Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Percent of Health Centers Providing Access to Monoclonal Antibody Therapy | 60.88% |
| Number of Doses of Monoclonal Antibodies Administered | 3,310 |
Methods in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Direct provision of monoclonal antibody therapies | 10.28% |
| Refer patients to another organization that provides monoclonal antibody therapies | 53.17% |
| None | 39.12% |
Challenges in Providing Access to Monoclonal Antibody Therapy
| Metrics | Value |
|---|---|
| Access to therapeutics | 11.94% |
| Patient awareness/education | 5.23% |
| Staffing capacity | 18.46% |
| Therapy administration/onsite logistics | 17.08% |
| Other | 5.05% |
| None | 60.88% |
Test Kit Distribution
| Metrics | Value |
|---|---|
| Percent of Health Centers that Distributed Test Kits Received through the HRSA COVID-19 Testing Supply Program | 26.91% |
| Number of Test Kits Distributed through the HRSA COVID-19 Testing Supply Program | 1,081,155 |
Test Kit Distribution Methods4
| Metrics | Value |
|---|---|
| Provide to Existing Health Center Patients | 83.28% |
| Provide to General Public Who Came to the Health Center | 60.75% |
| Provide at Special Vaccination Events (e.g., through mobile vans, pop-up clinics, school-based clinics, family vaccination clinics) | 25.26% |
| Provide at Other Community Events | 23.55% |
| Provide through direct outreach to specific populations (i.e., individuals experiencing homelessness, MSAWs, residents of public housing, individuals with limited English proficiency) | 32.08% |
| Other | 30.03% |
Oral Antiviral Medication Distribution
| Metrics | Value |
|---|---|
| Number of Health Centers that Provided COVID-19 Oral Antiviral Medication through the HRSA Health Center COVID-19 Therapeutics Program | 59 |
| Racial and/or Ethnic Minority Patients Who Received COVID-19 Oral Antiviral Medication5 | 63.02% |
Oral Antiviral Medication Distribution by Race and Ethnicity5
| Race/Ethnicity | Value |
|---|---|
| White, Non-Hispanic/Latino Patients | 23.49% |
| White, Hispanic/Latino Patients | 49.52% |
| Black/African American, Non-Hispanic/Latino Patients | 0.00% |
| Black/African American, Hispanic/Latino Patients | 0.32% |
| Asian Patients3 | 3.81% |
| American Indian/Alaska Native Patients3 | 1.11% |
| Native Hawaiian/Other Pacific Islander Patients3 | 0.48% |
| Patients with More Than One Race3 | 1.90% |
| Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 5.87% |
| Non-Hispanic/Latino Ethnicity Patients (Unreported/Refused to Report Race) | 0.48% |
| Unreported/Refused to Report Race and Ethnicity | 5.40% |
Oral Antiviral Medication Distribution by Special/Vulnerable Population5
| Metrics | Value |
|---|---|
| Migratory/Agricultural Workers | 0.79% |
| Patients Experiencing Homelessness | 1.27% |
| Patients Who Are Residents of Public Housing | 6.19% |
| Patients with Limited English Proficiency | 10.95% |
| Children Under 18 Years of Age | 0.32% |
Results from States and Territories
Select a measure on the dropdown menu to view by state or territory.
- Alabama
- Alaska
- American Samoa
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Federated States of Micronesia
- Florida
- Georgia
- Guam
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Marshall Islands
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Northern Mariana Islands
- Ohio
- Oklahoma
- Oregon
- Palau
- Pennsylvania
- Puerto Rico
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Virgin Islands
- Washington
- West Virginia
- Wisconsin
- Wyoming
1 The reported number of patients tested does not represent the same patients included in the reported number of patients tested positive due to a lag between the date the specimen is collected and the availability of test results. Positivity rates cannot be inferred by dividing patients tested positive by patients tested for this reason.
2 Percentages may not add to 100% due to rounding to the hundredths.
3 Includes Hispanic/Latino and Non-Hispanic/Latino.
4 Percentages are calculated using the number of health centers that have distributed test kits received through the HRSA COVID-19 Testing Supply Program as the denominator.
5 Percentages are calculated using the number of health centers that have distributed courses of COVID-19 oral antiviral medication received through the HRSA Health Center COVID-19 Therapeutics Program as the denominator.
